• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Airway proteases: an emerging drug target for influenza and other respiratory virus infections

tetano

Editor, Senior Moderator
Curr Opin Virol. 2017 Apr 14;24:16-24. doi: 10.1016/j.coviro.2017.03.018. [Epub ahead of print]
[h=1]Airway proteases: an emerging drug target for influenza and other respiratory virus infections.[/h] Laporte M[SUP]1[/SUP], Naesens L[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] To enter into airway epithelial cells, influenza, parainfluenza- and coronaviruses rely on host cell proteases for activation of the viral protein involved in membrane fusion. One protease, transmembrane protease serine 2 (TMPRSS2) was recently proven to be crucial for hemagglutinin cleavage of some human influenza viruses. Since the catalytic sites of the diverse serine proteases linked to influenza, parainfluenza- and coronavirus activation are structurally similar, active site inhibitors of these airway proteases could have broad therapeutic applicability against multiple respiratory viruses. Alternatively, superior selectivity could be achieved with allosteric inhibitors of TMPRSS2 or another critical protease. Though still in its infancy, airway protease inhibition represents an attractive host-cell targeting approach to combat respiratory viruses such as influenza.
Copyright ? 2017 The Authors. Published by Elsevier B.V. All rights reserved.


PMID: 28414992 DOI: 10.1016/j.coviro.2017.03.018
 
Back
Top Bottom